Business Description
Alector Inc
NAICS : 325412
SIC : 2834
ISIN : US0144421072
Compare
Compare
Traded in other countries / regions
ALEC.USA0Z2.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2019-02-07Description
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.64 | |||||
| Equity-to-Asset | 0.23 | |||||
| Debt-to-Equity | 0.43 | |||||
| Debt-to-EBITDA | -0.3 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -2.72 | |||||
| Beneish M-Score | -1.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -26.1 | |||||
| 3-Year EBITDA Growth Rate | -57.5 | |||||
| 3-Year EPS without NRI Growth Rate | -39.8 | |||||
| 3-Year Book Growth Rate | -29.6 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.64 | |||||
| 9-Day RSI | 45.72 | |||||
| 14-Day RSI | 49.53 | |||||
| 3-1 Month Momentum % | 14.66 | |||||
| 6-1 Month Momentum % | -29.63 | |||||
| 12-1 Month Momentum % | -69.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.34 | |||||
| Quick Ratio | 3.34 | |||||
| Cash Ratio | 3.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.5 | |||||
| Shareholder Yield % | 0.55 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -165.25 | |||||
| Net Margin % | -139.74 | |||||
| EBITDA Margin % | -155.75 | |||||
| FCF Margin % | -260.46 | |||||
| ROE % | -92.15 | |||||
| ROA % | -23.75 | |||||
| ROIC % | -98.17 | |||||
| 3-Year ROIIC % | 332.12 | |||||
| ROC (Joel Greenblatt) % | -365.08 | |||||
| ROCE % | -38.24 | |||||
| Moat score | 5 | |||||
| Tariff score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.68 | |||||
| PB Ratio | 1.58 | |||||
| Price-to-Tangible-Book | 1.58 | |||||
| EV-to-EBIT | 1.17 | |||||
| EV-to-EBITDA | 1.25 | |||||
| EV-to-Revenue | -1.94 | |||||
| EV-to-Forward-Revenue | 0.73 | |||||
| EV-to-FCF | 0.75 | |||||
| Price-to-GF-Value | 0.38 | |||||
| Price-to-Net-Current-Asset-Value | 2.83 | |||||
| Price-to-Net-Cash | 3.66 | |||||
| Earnings Yield (Greenblatt) % | 85.47 | |||||
| FCF Yield % | -153.4 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers